Clinical Trial Update: Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial planned to evaluate tunlametinib plus AG and Cetuximab beta as first-line therapy for advanced non-resectable pancreatic cancer. The study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• AG
• Cetuximab (cetuximab)
• Tunlametinib (tunlametinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Pancreatic Cancer Non-resectable | Phase 4 | Status: NOT_YET_RECRUITING